News

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce it has awarded the CMTA Center of Excellence ...

Exciting progress from CMTA’s Strategy To Accelerate Research (STAR) program is once again highlighted with a recent publication celebrating a decade of CMT genomics discovery made possible by the GENESIS platform. This critically important CMTA-funded work, published in Experimental Neurology, ...

The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA-STAR Alliance Partner NMD Pharma A/S (NMD Pharma) on initiating its Phase II SYNAPSE-CMT trial. This significant milestone reflects a shared commitment to advancing therapeutic options for individuals living with CMT. The trial’s first patient ...

The Charcot-Marie-Tooth Association (CMTA), through its strategic alliance with the Inherited Neuropathy Consortium (INC), is proud to announce the 2025 Inherited Neuropathy Fellowship. This one-year fellowship highlights how the CMTA-INC alliance drives progress by equipping the next generation of clinicians ...

CMTA strengthens its role as the leading force in comprehensive CMT research, forging a strategic alliance with the Inherited Neuropathy Consortium The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments to patients, today ...